Table 3 Stratification analysis of APOA1 -75 G/A polymorphisms in renal cancer cases
From: Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk
Cases | GG | GA | AA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
n (%) | OR (95 %CI) | P | n (%) | OR (95 %CI) | P | n (%) | OR (95 %CI) | P | ||
Grade | 216 | 108 (50.0) | 1 (Reference) | 66 (30.6) | 1 (Reference) | 42 (19.4) | 1 (Reference) | |||
1 | 55 | 28 (50.9) | 1.02 (0.61,1.70) | 0.95 | 15 (27.3) | 0.89 (0.47,1.68) | 0.73 | 12 (21.8) | 1.12 (0.55,2.27) | 0.75 |
2 | 129 | 64 (49.6) | 0.99 (0.68,1.45) | 0.97 | 42 (32.6) | 1.07 (0.68,1.66) | 0.78 | 23 (17.8) | 0.92 (0.53,1.59) | 0.76 |
3 + 4 | 32 | 16 (50.0) | 1.00 (0.53,1.90) | 1.00 | 9 (28.1) | 0.92 (0.42,2.03) | 0.84 | 7 (21.9) | 1.13 (0.47,2.72) | 0.79 |
Tumor classification | 216 | 108 (50.0) | 1 (Reference) | 66 (30.6) | 1 (Reference) | 42 (19.4) | 1 (Reference) | |||
T1 | 103 | 55 (53.4) | 1.07 (0.72,1.59) | 0.75 | 29 (28.2) | 0.92 (0.56,1.51) | 0.75 | 19 (18.4) | 0.95 (0.53,1.71) | 0.86 |
T2 | 49 | 22 (44.9) | 0.90 (0.52,1.56) | 0.70 | 16 (32.7) | 1.07 (0.57,2.00) | 0.84 | 11 (22.4) | 1.16 (0.56,2.40) | 0.70 |
T3 | 57 | 28 (49.1) | 0.98 (0.59,1.63) | 0.95 | 19 (33.3) | 1.09 (0.61,1.96) | 0.77 | 10 (17.6) | 0.90 (0.43,1.91) | 0.79 |
T4 | 7 | 3 (42.8) | 0.86 (0.22,3.38) | 0.83 | 2 (28.6) | 0.94 (0.19,4.61) | 0.93 | 2 (28.6) | 1.47 (0.29,7.32) | 0.64 |
Lymph node invasion status | 216 | 108 (50.0) | 1 (Reference) | 66 (30.6) | 1 (Reference) | 42 (19.4) | 1 (Reference) | |||
Negative | 199 | 99 (49.7) | 0.99 (0.71,1.39) | 0.98 | 61 (30.7) | 1.00 (0.67,1.49) | 0.99 | 39 (19.6) | 1.01 (0.63,1.62) | 0.97 |
Positive | 17 | 9 (52.9) | 1.06 (0.46,2.45) | 0.89 | 5 (29.4) | 0.96 (0.34,2.71) | 0.94 | 3 (17.7) | 0.91 (0.26,3.24) | 0.88 |
Distant metastasis status | 216 | 108 (50.0) | 1 (Reference) | 66 (30.6) | 1 (Reference) | 42 (19.4) | 1 (Reference) | |||
Negative | 188 | 99 (52.7) | 1.05 (0.75,1.47) | 0.76 | 59 (31.4) | 1.03 (0.69,1.54) | 0.90 | 30 (15.9) | 0.82 (0.49,1.36) | 0.45 |
Positive | 28 | 9 (32.1) | 0.64 (0.29,1.41) | 0.27 | 7 (25.0) | 0.82 (0.34,1.96) | 0.65 | 12 (42.9) | 2.20 (1.04,4.68) | 0.04 |
Pathology | 216 | 108 (50.0) | 1 (Reference) | 66 (30.6) | 1 (Reference) | 42 (19.4) | 1 (Reference) | |||
Clear cell carcinoma | 197 | 99 (50.2) | 1.01 (0.72,1.40) | 0.98 | 60 (30.5) | 1.00 (0.67,1.49) | 0.99 | 38 (19.3) | 0.99 (0.61,1.60) | 0.97 |
Granular cell carcinoma | 15 | 7 (46.7) | 0.93 (0.37,2.36) | 0.88 | 5 (33.3) | 1.09 (0.38,3.11) | 0.87 | 3 (20.0) | 1.03 (0.29,3.71) | 0.97 |
Chromophobe cell carcinoma | 4 | 2 (50.0) | 1.00 (0.18,5.55) | 1.00 | 1 (25.0) | 0.82 (0.09,7.45) | 0.86 | 1 (25.0) | 1.29 (0.14,11.79) | 0.82 |